SLXN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Silexion Therapeutics Corp (SLXN) is not a strong buy at this time for a beginner investor with a long-term focus. The company is in the early stages of development with no revenue growth, significant net income losses, and no recent positive trading trends or news catalysts. While the analyst rating is positive with a high price target, the lack of strong financial performance, technical signals, and trading sentiment suggests holding off on this investment for now.
The MACD is positive and expanding, indicating a potential upward momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a lack of strong bullish momentum. The stock is trading near its pivot point of 1.579, with resistance at 1.777 and support at 1.457.
The company is targeting unmet needs in KRAS-driven cancers with a novel siRNA platform, and it is positioned to enter late-stage clinical development with regulatory filings in Israel, Germany, and the EU in the near term. Analyst coverage initiated with a Buy rating and a $6 price target.
The company has no revenue growth, significant net income losses (-72.50% YoY), and a sharp decline in EPS (-97.99% YoY). There are no significant trading trends from hedge funds or insiders, and no recent news or congress trading data to support the stock.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -$3,262,000 (-72.50% YoY), and a sharp decline in EPS to -2.88 (-97.99% YoY). Gross margin remains at 0%.
Litchfield Hills analyst initiated coverage with a Buy rating and a $6 price target, citing the company's novel approach to KRAS-driven cancers and its siRNA platform. The company is expected to make regulatory filings in Q4 2025 and Q1 2026.
